NA
NAMS.US NewAmsterdam Pharma Company N.V. Ordinary Shares
- Market cap
- USD 2.33B
- P/E
- -
- P/B
- 3.83x
- ROE
- -27.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NAMS.US undervalued?
Graham numberThe Graham number of NewAmsterdam Pharma Company N.V. Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NewAmsterdam Pharma Company N.V. Ordinary Shares fundamental analysis
No fundamental analysis for NewAmsterdam Pharma Company N.V. Ordinary Shares yet.
NewAmsterdam Pharma Company N.V. Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial fo…
Full company profileNewAmsterdam Pharma Company N.V. Ordinary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NewAmsterdam Pharma Company N.V. Ordinary Shares annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 103M | 14.1M | 45.6M | 22.5M | 34.5M |
| Gross Profit | - | -14.6K | 103M | 14.1M | 45.6M | 22.4M | 33.9M |
| Operating Income | -6.63M | -35.0M | -3.56M | -183M | -176M | -226M | -223M |
| EBITDA | -6.63M | -41.4M | -22.3M | -177M | -241M | -242M | -173M |
| Net Income | -7.02M | -41.8M | -22.6M | -177M | -242M | -204M | -173M |
| EPS | -0.40 | -2.35 | -1.19 | -2.15 | -2.56 | -1.78 | -1.40 |
| Balance Sheet | |||||||
| Total Assets | 140M | 68.0M | 478M | 347M | 865M | 769M | 688M |
| Total Liabilities | 12.4M | 11.4M | 48.4M | 58.7M | 107M | 85.9M | 57.2M |
| Shareholders' Equity | 127M | 56.6M | 430M | 288M | 758M | 683M | 631M |
| Cash & Short-term Investments | 1.37M | 60.4M | 468M | 340M | 834M | 636M | 628M |
| Total Debt | 11.7M | 187K | 126K | 60.0K | 448K | 202K | 76.0K |
| Cash Flow | |||||||
| Operating Cash Flow | -7.34M | -29.5M | 10.7M | -141M | -159M | -148M | -146M |
| Capital Expenditure | 16.0K | 24.0K | 221K | 24.0K | 672K | 246K | 393K |
| Free Cash Flow | -7.36M | -29.5M | 10.4M | -141M | -159M | -148M | -147M |
| Ratios | |||||||
| ROE | -5.5% | -73.8% | -5.3% | -61.4% | -31.9% | -29.8% | -27.5% |
| ROA | -5.0% | -61.5% | -4.7% | -51.0% | -27.9% | -26.5% | -25.2% |
| Net Profit Margin | - | - | -22.0% | -1,255.8% | -530.3% | -905.7% | -501.7% |
| Debt to Equity | 0.09x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NewAmsterdam Pharma Company N.V. Ordinary Shares dividends
NewAmsterdam Pharma Company N.V. Ordinary Shares has not paid dividends in the last 6 fiscal years.
Last stock split: 1:1 on Nov 23, 2022.
Who owns NewAmsterdam Pharma Company N.V. Ordinary Shares
- Insiders 0.95%
- Institutions 99.05%
- Public & others 0.00%
- Shares outstanding 120M
- Free float 81.9M
Top funds holding NAMS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 9.56M | 7.98% | +3.20% | Sep 2026 |
| Capital Group Global Equity Canada F | 2.52M | 2.10% | 0.00% | Jun 2026 |
| Fidelity Contrafund | 2.30M | 1.92% | -0.92% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 2.20M | 1.84% | -3.69% | Sep 2026 |
| American Funds New Economy A | 1.25M | 1.04% | +30.14% | Sep 2026 |
| Janus Henderson Global Life Sciences D | 1.16M | 0.97% | 0.00% | Sep 2026 |
| Janus Global Life Science AUSD | 1.13M | 0.95% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 980K | 0.82% | +15.62% | Aug 2026 |
| Polar Capital Biotech S Inc | 823K | 0.69% | 0.00% | Sep 2026 |
| Capital Group U.S. Small and Mid Cap ETF | 774K | 0.65% | +0.09% | Oct 2026 |
| Candriam Eqs L Biotech C USD Cap | 670K | 0.56% | -2.88% | Apr 2026 |
| American Century Small Cap Growth Inv | 656K | 0.55% | +25.05% | Sep 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 632K | 0.53% | +31.73% | Jun 2026 |
| Fidelity Advisor Biotechnology I | 618K | 0.52% | +37.97% | Sep 2026 |
| iShares Biotechnology ETF | 603K | 0.50% | -0.19% | Oct 2026 |
| Janus Henderson Triton D | 570K | 0.48% | 0.00% | Sep 2026 |
| JPMorgan Small Cap Growth A | 536K | 0.45% | -0.61% | Sep 2026 |
| PGIM Jennison Health Sciences Z | 534K | 0.45% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 524K | 0.44% | 0.00% | Aug 2026 |
| Fidelity Advisor Health Care I | 505K | 0.42% | +5.15% | Sep 2026 |
Top institutions holding NAMS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 18.1M | 15.10% | +6.76% | Jun 2026 |
| Capital World Investors | 12.2M | 10.21% | +10.10% | Jun 2026 |
| FMR Inc | 10.3M | 8.63% | +17.95% | Jun 2026 |
| RA Capital Management, LLC | 9.55M | 7.97% | 0.00% | Jun 2026 |
| FCPM III SERVICES BV | 8.49M | 7.09% | -7.70% | Jun 2026 |
| Deerfield Management Co | 4.26M | 3.56% | 0.00% | Jun 2026 |
| Viking Global Investors LP | 4.20M | 3.51% | 0.00% | Jun 2026 |
| Bain Capital Life Sciences Investors, LLC | 3.81M | 3.18% | -47.90% | Jun 2026 |
| Maverick Capital Ltd | 3.27M | 2.73% | +49.46% | Jun 2026 |
| Duquesne Family Office LLC | 3.07M | 2.56% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 2.54M | 2.12% | 0.00% | Jun 2026 |
| Medicxi Ventures Management (Jersey) Ltd | 2.21M | 1.84% | -17.41% | Jun 2026 |
| Jennison Associates LLC | 2.10M | 1.75% | -23.56% | Jun 2026 |
| Capital Research & Mgmt Co - Division 3 | 1.84M | 1.54% | +6.89% | Sep 2026 |
| Orbis Allan Gray Ltd | 1.75M | 1.46% | 0.00% | Jun 2026 |
| Polar Capital Holdings PLC | 1.72M | 1.44% | -39.10% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.54M | 1.29% | -20.63% | Jun 2026 |
| Castle Hook Partners LP | 1.37M | 1.14% | +31.49% | Jun 2026 |
| AllianceBernstein L.P. | 1.26M | 1.05% | +5.05% | Jun 2026 |
| Ameriprise Financial Inc | 1.25M | 1.05% | +66.46% | Jun 2026 |
NewAmsterdam Pharma Company N.V. Ordinary Shares company profile
- Company name
- NewAmsterdam Pharma Company N.V. Ordinary Shares
- Ticker
- NAMS.US
- ISIN
- NL00150012L7
- Exchange
- USA Stocks
- Listed since
- Nov 23, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Fiscal year end
- December
- Address
- Gooimeer 2-35, Naarden, Netherlands, 1411 DC
- Phone
- 31 35 206 2971
- Website
- newamsterdampharma.com
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V. Ordinary Shares management
10- Dr. Michael Harvey Davidson FACC, Facp., M.D.CEO, President & Executive Director · born 1956
- Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.Founder, Chief Scientific Officer, Member of Executive Board & Director · born 1954
- Mr. Mayur Amrat SomaiyaChief Financial Officer · born 1974
- Mr. Robert W. Gunning CPA, CGMAPrincipal Accounting Officer, VP & Controller · born 1971
- Mr. Matthew PhilippeExecutive VP & Head of Investor Relations
- Mr. Michael F. Marino Esq.Chief Legal Officer & Corporate Secretary · born 1976
- Mr. Chris DeluzioExecutive Vice President of Sales Enterprise Operations
- Ms. Maryellen McQuadeChief People Officer
- Ms. Juliette Audet M.B.A., M.Sc.Chief Strategy & Business Officer · born 1987
- Dr. Marc Ditmarsch M.D.Chief Development Officer · born 1967